x
[contact-form-7 404 "Not Found"]

Category: Cancer

Cancer

Feb2014

Effective Design of Multi-Marker Diagnostic Tests for Personalized Medicine

Tersan Pharmaceuticals Ltd releases a video to illustrate the use of its KEM® data mining technology in the effective design of multi-marker diagnostic tests for personalized medicine; KEM® identifies the shortest and most accurate signatures. The video is available on our Vimeo and YouTube channels or can be viewed below.   One size doesn’t fit all! […]

Read More
Cancer

Dec2013

BioPharmAnalyses interview – Tersan Pharmaceuticals Ltd : trois nouveaux projets lancés en 2013 pour des solutions personnalisées contre le cancer

Tersan Pharmaceuticals Ltd, société spécialiste de l’analyse des données cliniques et des tests diagnostiques pour la médecine personnalisée, vient d’annoncer le lancement du projet ExtempoRMN. A travers ce projet qui associe cette spin-off de l’Institut Pasteur au groupe d’instrumentation scientifique Bruker BioSpin, aux Hôpitaux universitaires de Strasbourg et au laboratoire Icube de l’université de Strasbourg, l’objectif […]

Read More
Cancer

Dec2013

Biotech Finances audio interview – Tersan Pharmaceuticals Ltd sélectionnée par deux consortia en oncologie

L’entreprise parisienne Tersan Pharmaceuticals Ltd, spécialisée dans les outils informatiques d’aide à la décision clinique, a été retenue pour participer au projet alsacien ExtempoRMN. Celui-ci vise à développer une méthode innovante permettant d’établir le diagnostic des tissus cancéreux en temps réel. Quelques mois auparavant, Tersan Pharmaceuticals Ltd était sélectionnée dans le cadre de l’essai clinique international Winther […]

Read More
Cancer

Dec2013

Tersan Pharmaceuticals Ltd announces ExtempoNMR, a new partnership with the potential to revolutionize brain cancer surgery

Neuro-oncology diagnostic tool aims to give surgeons the ability in ‘real-time’ to discriminate brain tumor tissue from surrounding healthy tissue.Radical new approach utilizes High Resolution Magic Angle Spinning Nuclear Magnetic Resonance technology Links: Download English PDF | Download French PDF Paris, France, and Cambridge, Massachusetts USA, 10 December 2013 – Tersan Pharmaceuticals Ltd, developer of innovative […]

Read More
Cancer

Sep2013

DDN News interview – Off to the data mines

When Tersan Pharmaceuticals Ltd announced this summer that the WIN Consortium had chosen it to develop new personalized cancer medicine software through the consortium’s WINTHER trial, it wasn’t just a validation of Paris-based Tersan’s data management skills in life science, notes Dr. David Morley, Tersan’s vice president of computational technology — it was also a sign […]

Read More
Cancer

Jul2013

EP Vantage interview – Tersan’s algorithms could deliver bespoke cancer therapy

The advent of targeted cancer therapies has necessitated the development of companion diagnostics to identify those patients whose genetic makeup will allow them to benefit. But a patient’s gene signature is only one factor of many capable of affecting their response to a treatment. There is a demand, says Mohammad Afshar, CEO of Tersan Pharmaceuticals Ltd, […]

Read More